Biomarker research to improve clinical outcomes of peritoneal dialysis: consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) network

Christoph Aufricht, Robert Beelen, Matthias Eberl, Michel Fischbach, Donald Fraser, Achim Jörres, Klaus Kratochwill, Manuel LópezCabrera, Peter Rutherford, Claus Peter Schmitt, Nicholas Topley, Janusz Witowski

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Peritoneal dialysis (PD) therapy substantially requires biomarkers as tools to identify patients who are at the highest risk for PD-related complications and to guide personalized interventions that may improve clinical outcome in the individual patient. In this consensus article, members of the European Training and Research in Peritoneal Dialysis Network (EuTRiPD) review the current status of biomarker research in PD and suggest a selection of biomarkers that can be relevant to the care of PD patients and that are directly accessible in PD effluents. Currently used biomarkers such as interleukin-6, interleukin-8, ex vivo–stimulated interleukin-6 release, cancer antigen-125, and advanced oxidation protein products that were collected through a Delphi procedure were first triaged for inclusion as surrogate endpoints in a clinical trial. Next, novel biomarkers were selected as promising candidates for proof-of-concept studies and were differentiated into inflammation signatures (including interleukin-17, M1/M2 macrophages, and regulatory T cell/T helper 17), mesothelial-to-mesenchymal transition signatures (including microRNA-21 and microRNA-31), and signatures for senescence and inadequate cellular stress responses. Finally, the need for defining pathogen-specific immune fingerprints and phenotype-associated molecular signatures utilizing effluents from the clinical cohorts of PD patients and “omics” technologies and bioinformatics-biostatistics in future joint-research efforts was expressed. Biomarker research in PD offers the potential to develop valuable tools for improving patient management. However, for all biomarkers discussed in this consensus article, the association of biological rationales with relevant clinical outcomes remains to be rigorously validated in adequately powered, prospective, independent clinical studies.

Original languageEnglish
Pages (from-to)824-835
Number of pages12
JournalKidney International
Volume92
Issue number4
DOIs
Publication statusPublished - 1 Oct 2017

Cite this

Aufricht, Christoph ; Beelen, Robert ; Eberl, Matthias ; Fischbach, Michel ; Fraser, Donald ; Jörres, Achim ; Kratochwill, Klaus ; LópezCabrera, Manuel ; Rutherford, Peter ; Schmitt, Claus Peter ; Topley, Nicholas ; Witowski, Janusz. / Biomarker research to improve clinical outcomes of peritoneal dialysis : consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) network. In: Kidney International. 2017 ; Vol. 92, No. 4. pp. 824-835.
@article{b0996936948c4329b23d0ba672cbc421,
title = "Biomarker research to improve clinical outcomes of peritoneal dialysis: consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) network",
abstract = "Peritoneal dialysis (PD) therapy substantially requires biomarkers as tools to identify patients who are at the highest risk for PD-related complications and to guide personalized interventions that may improve clinical outcome in the individual patient. In this consensus article, members of the European Training and Research in Peritoneal Dialysis Network (EuTRiPD) review the current status of biomarker research in PD and suggest a selection of biomarkers that can be relevant to the care of PD patients and that are directly accessible in PD effluents. Currently used biomarkers such as interleukin-6, interleukin-8, ex vivo–stimulated interleukin-6 release, cancer antigen-125, and advanced oxidation protein products that were collected through a Delphi procedure were first triaged for inclusion as surrogate endpoints in a clinical trial. Next, novel biomarkers were selected as promising candidates for proof-of-concept studies and were differentiated into inflammation signatures (including interleukin-17, M1/M2 macrophages, and regulatory T cell/T helper 17), mesothelial-to-mesenchymal transition signatures (including microRNA-21 and microRNA-31), and signatures for senescence and inadequate cellular stress responses. Finally, the need for defining pathogen-specific immune fingerprints and phenotype-associated molecular signatures utilizing effluents from the clinical cohorts of PD patients and “omics” technologies and bioinformatics-biostatistics in future joint-research efforts was expressed. Biomarker research in PD offers the potential to develop valuable tools for improving patient management. However, for all biomarkers discussed in this consensus article, the association of biological rationales with relevant clinical outcomes remains to be rigorously validated in adequately powered, prospective, independent clinical studies.",
keywords = "epithelial–mesenchymal transition, peritonitis, proteomics, renal replacement therapy, surrogate markers, ultrafiltration failure",
author = "Christoph Aufricht and Robert Beelen and Matthias Eberl and Michel Fischbach and Donald Fraser and Achim J{\"o}rres and Klaus Kratochwill and Manuel L{\'o}pezCabrera and Peter Rutherford and Schmitt, {Claus Peter} and Nicholas Topley and Janusz Witowski",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.kint.2017.02.037",
language = "English",
volume = "92",
pages = "824--835",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "4",

}

Aufricht, C, Beelen, R, Eberl, M, Fischbach, M, Fraser, D, Jörres, A, Kratochwill, K, LópezCabrera, M, Rutherford, P, Schmitt, CP, Topley, N & Witowski, J 2017, 'Biomarker research to improve clinical outcomes of peritoneal dialysis: consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) network' Kidney International, vol. 92, no. 4, pp. 824-835. https://doi.org/10.1016/j.kint.2017.02.037

Biomarker research to improve clinical outcomes of peritoneal dialysis : consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) network. / Aufricht, Christoph; Beelen, Robert; Eberl, Matthias; Fischbach, Michel; Fraser, Donald; Jörres, Achim; Kratochwill, Klaus; LópezCabrera, Manuel; Rutherford, Peter; Schmitt, Claus Peter; Topley, Nicholas; Witowski, Janusz.

In: Kidney International, Vol. 92, No. 4, 01.10.2017, p. 824-835.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Biomarker research to improve clinical outcomes of peritoneal dialysis

T2 - consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) network

AU - Aufricht, Christoph

AU - Beelen, Robert

AU - Eberl, Matthias

AU - Fischbach, Michel

AU - Fraser, Donald

AU - Jörres, Achim

AU - Kratochwill, Klaus

AU - LópezCabrera, Manuel

AU - Rutherford, Peter

AU - Schmitt, Claus Peter

AU - Topley, Nicholas

AU - Witowski, Janusz

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Peritoneal dialysis (PD) therapy substantially requires biomarkers as tools to identify patients who are at the highest risk for PD-related complications and to guide personalized interventions that may improve clinical outcome in the individual patient. In this consensus article, members of the European Training and Research in Peritoneal Dialysis Network (EuTRiPD) review the current status of biomarker research in PD and suggest a selection of biomarkers that can be relevant to the care of PD patients and that are directly accessible in PD effluents. Currently used biomarkers such as interleukin-6, interleukin-8, ex vivo–stimulated interleukin-6 release, cancer antigen-125, and advanced oxidation protein products that were collected through a Delphi procedure were first triaged for inclusion as surrogate endpoints in a clinical trial. Next, novel biomarkers were selected as promising candidates for proof-of-concept studies and were differentiated into inflammation signatures (including interleukin-17, M1/M2 macrophages, and regulatory T cell/T helper 17), mesothelial-to-mesenchymal transition signatures (including microRNA-21 and microRNA-31), and signatures for senescence and inadequate cellular stress responses. Finally, the need for defining pathogen-specific immune fingerprints and phenotype-associated molecular signatures utilizing effluents from the clinical cohorts of PD patients and “omics” technologies and bioinformatics-biostatistics in future joint-research efforts was expressed. Biomarker research in PD offers the potential to develop valuable tools for improving patient management. However, for all biomarkers discussed in this consensus article, the association of biological rationales with relevant clinical outcomes remains to be rigorously validated in adequately powered, prospective, independent clinical studies.

AB - Peritoneal dialysis (PD) therapy substantially requires biomarkers as tools to identify patients who are at the highest risk for PD-related complications and to guide personalized interventions that may improve clinical outcome in the individual patient. In this consensus article, members of the European Training and Research in Peritoneal Dialysis Network (EuTRiPD) review the current status of biomarker research in PD and suggest a selection of biomarkers that can be relevant to the care of PD patients and that are directly accessible in PD effluents. Currently used biomarkers such as interleukin-6, interleukin-8, ex vivo–stimulated interleukin-6 release, cancer antigen-125, and advanced oxidation protein products that were collected through a Delphi procedure were first triaged for inclusion as surrogate endpoints in a clinical trial. Next, novel biomarkers were selected as promising candidates for proof-of-concept studies and were differentiated into inflammation signatures (including interleukin-17, M1/M2 macrophages, and regulatory T cell/T helper 17), mesothelial-to-mesenchymal transition signatures (including microRNA-21 and microRNA-31), and signatures for senescence and inadequate cellular stress responses. Finally, the need for defining pathogen-specific immune fingerprints and phenotype-associated molecular signatures utilizing effluents from the clinical cohorts of PD patients and “omics” technologies and bioinformatics-biostatistics in future joint-research efforts was expressed. Biomarker research in PD offers the potential to develop valuable tools for improving patient management. However, for all biomarkers discussed in this consensus article, the association of biological rationales with relevant clinical outcomes remains to be rigorously validated in adequately powered, prospective, independent clinical studies.

KW - epithelial–mesenchymal transition

KW - peritonitis

KW - proteomics

KW - renal replacement therapy

KW - surrogate markers

KW - ultrafiltration failure

UR - http://www.scopus.com/inward/record.url?scp=85027190628&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2017.02.037

DO - 10.1016/j.kint.2017.02.037

M3 - Review article

VL - 92

SP - 824

EP - 835

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -